FeesSafety
Pluang+

Visara starts Phase 2b trial of VIS-101 for wet AMD, testing longer treatment intervals vs standard care

Market News
18 Nov 2026, 14:00 WIB
GlobeNewsWire
View Source
Bullish
Visara starts Phase 2b trial of VIS-101 for wet AMD, testing longer treatment intervals vs standard care

Visara has dosed the first patient in its ASCEND Phase 2b trial evaluating VIS-101, a new drug for wet age-related macular degeneration (wet AMD). The study compares two doses of VIS-101 against aflibercept, the current standard treatment, aiming to see if VIS-101 can maintain disease control with fewer injections. Earlier Phase 2a results showed promising durability, with about half of patients needing no retreatment six months after initial doses. The trial in China will help determine the best dose and support a global Phase 3 program planned for 2027.

Visara's announcement of dosing the first patient in its ASCEND Phase 2b trial of VIS-101 provides context for health sector market activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 18, 2026 18:11 WIB: out of 150 priced US health-sector stocks, 64 rose and 75 fell. Notable movers include CTXR at USD 0.53 with a 1-day change of +2.16% and Pluang order activity of 90% Sell / 10% Buy, TAK at USD 21.20 down 2.03% with 100% Sell orders, and IOVA at USD 7.38 down 1.99%. Typical hold times range from 8 to 20 days.

More News

Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft's stock fell 2.27% to $506.24 following global outages affecting its Copilot, Teams, and Outlook services. The outages, attributed to server issues rather than cyberattacks, raised concerns amid broader software sector weakness. Oppenheimer...

Market News
Bearish
49 minutes ago
Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target Corporation reported earnings per share of $2.65, beating estimates of $2.08, and revenue of $27.1 billion, surpassing the $26.5 billion forecast. The company achieved its strongest quarterly sales growth in about five years, with net sales up...

Company Fundamentals
Bullish
55 minutes ago
Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics announced its participation in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City. CEO Daniel Barber will present on December 2 at 10:30 am ET, with one-on-one investor meetings schedu...

Market News
Neutral
1 hour ago
Raymond James upgrades Charles Schwab to Strong Buy as client assets hit $13.27T in Oct 2026

Raymond James upgrades Charles Schwab to Strong Buy as client assets hit $13.27T in Oct 2026

Raymond James upgraded Charles Schwab to Strong Buy following strong growth in October 2026. Client assets rose 12% year over year to $13.27 trillion, with core net new assets surging 50% to $66.5 billion, a record for the month. Schwab also opened 4...

Analyst Insights
Bullish
2 hours ago
SDVerse named CES Innovation Awards 2027 Honoree for AI-powered automotive software marketplace.

SDVerse named CES Innovation Awards 2027 Honoree for AI-powered automotive software marketplace.

SDVerse, a B2B automotive software marketplace founded by General Motors, Magna, and Wipro, was honored with a CES Innovation Award 2027 in the Enterprise Tech category. The platform uses AI and standardized technical data to help automakers and supp...

Others
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App